Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics Holdings, Inc. Common Stock
- Market cap
- $1.84B
Your view on COAG
Overview
What the company does, where it operates, and who runs it.
About Hemab Therapeutics Holdings, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Benny Sorensen
- Headquarters
- 101 Main Street, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Benny Sorensen
- Headquarters
- 101 Main Street, Cambridge, MA, US
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies.
The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency.
Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs.
Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Hemab Therapeutics Holdings, Inc. Common Stock. Starting points for Hemab Therapeutics Holdings, Inc. Common Stock: EPS -$2.00, beta 1.85 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Hemab Therapeutics Holdings, Inc. Common Stock. Trailing twelve-month EPS for Hemab Therapeutics Holdings, Inc. Common Stock stands at -$2.00. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
3 firms, last 12 months- Strong Buy0
- Buy3
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.57 | −$0.61 | −$2.97 | −$2.52 |
| Lowest estimate | −$0.58 | −$0.62 | −$2.98 | −$2.61 |
| Highest estimate | −$0.56 | −$0.59 | −$2.96 | −$2.41 |
| Number of analysts | 3 | 2 | 4 | 4 |
| A year ago | — | −$23.98 | −$2.331 | — |
| Growth vs a year ago | — | +97.5% | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Lowest estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Highest estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Number of analysts | 0 | 0 | 0 | 0 |
| A year ago | — | $0.00 | $0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Hemab Therapeutics Holdings, Inc. Common Stock. Hemab Therapeutics Holdings, Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| DMRADamora Therapeutics, Inc. | Healthcare | Biotechnology | $1.4B | ||
| IRONDisc Medicine, Inc. | Healthcare | Biotechnology | $2.9B | ||
| QUREuniQure N.V. | Healthcare | Biotechnology | $1.4B | ||
| RLYBRallybio Corporation | Healthcare | Biotechnology | $83.3M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | Healthcare | NASDAQ | $2.0B | ||
| AURAAura Biosciences, Inc. | Healthcare | NASDAQ | $715.0M | ||
| AURXNuo Therapeutics, Inc. | Healthcare | OTC | $72.4M | ||
| AUTLAutolus Therapeutics plc | Healthcare | NASDAQ | $241.7M | ||
| AVBPArriVent BioPharma, Inc. Common Stock | Healthcare | NASDAQ | $544.1M | ||
| AVCTFAvacta Group Plc | Healthcare | OTC | $372.9M | ||
| AVE.AXAvecho Biotechnology Limited | Healthcare | ASX | — | ||
| AVEFFAvecho Biotechnology Limited | Healthcare | OTC | $13.4M | ||
| AVIRAtea Pharmaceuticals, Inc. | Healthcare | NASDAQ | $318.0M | ||
| AVLNAvalyn Pharma Inc. Common Stock | Healthcare | NASDAQ | $1.3B | ||
| AVTXAvalo Therapeutics, Inc. | Healthcare | NASDAQ | $390.9M | ||
| AVXLAnavex Life Sciences Corp. | Healthcare | NASDAQ | $54.8M | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| XBIState Street SPDR S&P Biotech ETF | $10.0B in assets | 0.22% | |
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.03% | |
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.01% | |
| TMSLT. Rowe Price Small-Mid Cap ETF | $3.2B in assets | 0.05% | |
| VTWGVanguard Russell 2000 Growth ETF | $1.4B in assets | 0.03% | |
| FBCGFidelity Blue Chip Growth ETF | $7.3B in assets | 0.03% | |
| RSSLGlobal X - Russell 2000 ETF | $1.4B in assets | 0.03% | |
Largest holders first, then the funds most concentrated in COAG.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Hemab Therapeutics Holdings, Inc. Common Stock, and how their positions are changing. At a $1.84B market value, institutional positions materially move Hemab Therapeutics Holdings, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Hemab Therapeutics Holdings, Inc. Common Stock executives and directors. Shares of Hemab Therapeutics Holdings, Inc. Common Stock have traded between $23.00 and $53.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Hemab Therapeutics Holdings, Inc. Common Stock. Coverage tracks Hemab Therapeutics Holdings, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Hemab Therapeutics Holdings, Inc. Common Stock.